Literature DB >> 30688681

Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report.

Alexander M Girgis1, Eugene Golts2, Doug Humber3, Dalia A Banks1.   

Abstract

Heparin is the only well-established anticoagulant medication for cardiopulmonary bypass making selecting an alternative anticoagulant challenging in patients with heparin-induced thrombocytopenia. Other anticoagulant medications can cause significant postoperative bleeding, especially in patients with end-stage renal disease. We present a case of a 63-year-old woman requiring aortic valve replacement with a history of heparin-induced thrombocytopenia and end-stage renal disease. Cangrelor and heparin were successfully used during cardiopulmonary bypass, offering an option for anticoagulation management for a uniquely challenging patient population.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30688681     DOI: 10.1213/XAA.0000000000000969

Source DB:  PubMed          Journal:  A A Pract        ISSN: 2575-3126


  2 in total

1.  Heparin-Induced Thrombocytopenia and Cardiac Surgery: Can We Do It All With Cangrelor?

Authors:  Kenichi A Tanaka; Reney Henderson; Brittney Williams
Journal:  A A Pract       Date:  2019-11-01

2.  In Response.

Authors:  Alexander M Girgis; Dalia A Banks
Journal:  A A Pract       Date:  2019-11-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.